StockMarketWire.com - Scancell has narrowed its H1 pretax loss to GBP1.4m, from GBP1.5m. Its cash balance at Oct. 31, 2015, was GBP1.8m, versus GBP3.1m a year ago.

Joint-CEO Richard Goodfellow said:

"Scancell is in the midst of an exciting transformation. Our focus on the US has resulted in the appointment of Dr Keith Flaherty, one of the world leaders in melanoma clinical research as Principal Investigator for our planned SCIB1/checkpoint inhibitor combination study.

"The SCIB1 survival data, especially in patients with resected disease, is extremely encouraging. All 20 patients with resected Stage III/IV disease remain alive and only five have any evidence of disease progression.

"The strength of the Moditope platform has been endorsed by the publication of data supporting its scientific basis in Cancer Research, one of the most influential cancer journals in the world.

"We have strengthened the clinical development team with the appointment of Dr Peter Brown, former Global Head of Oncology at Teva Pharmaceuticals and recently appointed Dr John Chiplin as Chairman, both of whom are US based.

"We are attracting renewed interest from both investors and pharmaceutical companies on both sides of the Atlantic.

"Cancer immunotherapy is becoming one of the most important clinical advances of our generation and I have never been more optimistic about the Company, its research and the potential for future growth."




At 9:34am: [LON:SCLP] Scancell Holdings PLC share price was -0.75p at 17.25p



Story provided by StockMarketWire.com